Segmentation and classification support for downstream calcium scoring; adjunctive information only and not a stand-alone diagnostic tool.
Images and patients
CT/CTA · Heart/Coronary Arteries
Key limitation
Keep in mind: Excluded patients include pre-existing cardiac devices/electrodes, established ischemic disease such as grafts, stents, or PTCA, and thoracic metallic devices. Use with GE or Siemens equipment or subsidiaries is recommended; other manufacturers are not recommended. The packet is internally inconsistent about gated status in a comparison paragraph, so gated support is not inferred beyond the non-contrast CT-heart indication.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automatic coronary-artery calcium plaque segmentation for downstream calcium scoring.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Coronary Arteries Input: Non-contrast CT heart calcium-score studies from adults aged 30 and older, with GE or Siemens equipment or subsidiaries recommended; exclusions include cardiac devices/electrodes, established ischemic disease, and thoracic metallic devices.
Who uses it?Intended users: Trained healthcare professionals responsible for patient-management decisions under standard of care.
What does the software produce?Output: DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.
What is its most important limitation?Key limitation: Excluded patients include pre-existing cardiac devices/electrodes, established ischemic disease such as grafts, stents, or PTCA, and thoracic metallic devices. Use with GE or Siemens equipment or subsidiaries is recommended; other manufacturers are not recommended. The packet is internally inconsistent about gated status in a comparison paragraph, so gated support is not inferred beyond the non-contrast CT-heart indication.
Evidence takeaway. Evidence from the reviewed source record: FDA retrospective cohort study included 422 adults aged 30 and older with non-contrast calcium-score CT and heart coverage; ground truth used three annotators and majority voting, with at least 50% of ground-truth data from multiple U.S. locations. FDA testing used segmentation Dice, Agatston-category accuracy, vessel-classification Dice, precision/recall, and agreement analyses. The packet states acceptance criteria of at least 80% accuracy/Dice with a 95% CI lower bound at least 75%, and reports mean Agatston-category accuracies exceeding 94% with lower bounds above 75%; it also reports no specific site count.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automatic coronary-artery calcium plaque segmentation for downstream calcium scoring.
Non-contrast CT heart calcium-score studies from adults aged 30 and older, with GE or Siemens equipment or subsidiaries recommended; exclusions include cardiac devices/electrodes, established ischemic disease, and thoracic metallic devices.
DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.
Excluded patients include pre-existing cardiac devices/electrodes, established ischemic disease such as grafts, stents, or PTCA, and thoracic metallic devices. Use with GE or Siemens equipment or subsidiaries is recommended; other manufacturers are not recommended. The packet is internally inconsistent about gated status in a comparison paragraph, so gated support is not inferred beyond the non-contrast CT-heart indication.
FDA retrospective cohort study included 422 adults aged 30 and older with non-contrast calcium-score CT and heart coverage; ground truth used three annotators and majority voting, with at least 50% of ground-truth data from multiple U.S. locations. FDA testing used segmentation Dice, Agatston-category accuracy, vessel-classification Dice, precision/recall, and agreement analyses. The packet states acceptance criteria of at least 80% accuracy/Dice with a 95% CI lower bound at least 75%, and reports mean Agatston-category accuracies exceeding 94% with lower bounds above 75%; it also reports no specific site count.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA retrospective cohort study included 422 adults aged 30 and older with non-contrast calcium-score CT and heart coverage; ground truth used three annotators and majority voting, with at least 50% of ground-truth data from multiple U.S. locations. FDA testing used segmentation Dice, Agatston-category accuracy, vessel-classification Dice, precision/recall, and agreement analyses. The packet states acceptance criteria of at least 80% accuracy/Dice with a 95% CI lower bound at least 75%, and reports mean Agatston-category accuracies exceeding 94% with lower bounds above 75%; it also reports no specific site count.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
TeraRecon Cardiovascular.Calcification.CT regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K250288
Samplen=422
IndependenceIndependence not established
K250288
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K250288. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast CT heart calcium-score studies from adults aged 30 and older, with GE or Siemens equipment or subsidiaries recommended; exclusions include cardiac devices/electrodes, established ischemic disease, and thoracic metallic devices.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Containerized application on off-the-shelf hardware or a cloud platform; DICOM result files are viewable in DICOM-compliant systems and may be used by external viewers. Exact interfaces, versions, and current deployment configuration are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the algorithm as image processing software deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The TeraRecon Cardiovascular.Calcification.CT algorithm is an image processing software device that can be deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform." … "is a software as a medical device (SaMD) deployed as a containerized application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the algorithm as image processing software deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The TeraRecon Cardiovascular.Calcification.CT algorithm is an image processing software device that can be deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform." … "is a software as a medical device (SaMD) deployed as a containerized application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Containerized application on off-the-shelf hardware or a cloud platform; DICOM result files are viewable in DICOM-compliant systems and may be used by external viewers. Exact interfaces, versions, and current deployment configuration are not established.
TeraRecon announces it has been recognized as an ISO 27001:2022 certified company, maintaining an information security management system with documented processes for managing sensitive company information, HR processes, and IT systems; the announcement names TeraRecon's Intuition product and Eureka Clinical AI platform.
Vendor-wide
Checked 2026-10-27
Vendor statement; the certificate was not read (a certificate PDF is hosted on the same owning domain). Applicant name variants (TeraRecon Inc. with punctuation/case variants) are bridged via the identical distinctive name. Exact-release scope is not established.
ACR AI Central provides an exact-submission model card for TeraRecon Cardiovascular.Calcification.CT; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K250288 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Assists trained professionals with coronary-vessel, lumen, vessel-wall, plaque and stenosis visualization and measurements from CCTA; it does not replace clinical judgment.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.